|
1
|
Joensuu H, Hohenberger P and Corless CL:
Gastrointestinal stromal tumour. Lancet. 382:973–983. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Khanderia E, Markar SR, Acharya A, Kim Y,
Kim YW and Hanna GB: The influence of gastric cancer screening on
the stage at diagnosis and survival: A meta-analysis of comparative
studies in the far East. J Clin Gastroenterol. 50:190–197. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sugano K: Screening of gastric cancer in
Asia. Best Pract Res Clin Gastroenterol. 29:895–905. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Markar SR, Mikhail S, Malietzis G,
Athanasiou T, Mariette C, Sasako M and Hanna GB: Influence of
surgical resection of hepatic metastases from gastric
adenocarcinoma on long-term survival: Systematic review and pooled
analysis. Ann Surg. 263:1092–1101. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen XZ, Wen L, Rui YY, Liu CX, Zhao QC,
Zhou ZG, Hu JK and Liu Y: Long-term survival outcomes of
laparoscopic versus open gastrectomy for gastric cancer: A
systematic review and meta-analysis. Medicine (Baltimore).
94:e4542015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Coccolini F, Cotte E, Glehen O, Lotti M,
Poiasina E, Catena F, Yonemura Y and Ansaloni L: Intraperitoneal
chemotherapy in advanced gastric cancer. Meta-analysis of
randomized trials. Eur J Surg Oncol. 40:12–26. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tan IB, Ivanova T, Lim KH, Ong CW, Deng N,
Lee J, Tan SH, Wu J, Lee MH, Ooi CH, et al: Intrinsic subtypes of
gastric cancer, based on gene expression pattern, predict survival
and respond differently to chemotherapy. Gastroenterology.
141:476–485, e1-485.e11. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sun Z, Song X, Li X, Su T, Qi S, Qiao R,
Wang F, Huan Y, Yang W, Wang J, et al: In vivo multimodality
imaging of miRNA-16 iron nanoparticle reversing drug resistance to
chemotherapy in a mouse gastric cancer model. Nanoscale.
6:14343–14353. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Endo F, Nishizuka SS, Kume K, Ishida K,
Katagiri H, Ishida K, Sato K, Iwaya T, Koeda K and Wakabayashi G: A
compensatory role of NF-κB to p53 in response to 5-FU-based
chemotherapy for gastric cancer cell lines. PLoS One. 9:e901552014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tang X, Hu G, Xu C, Ouyang K, Fang W,
Huang W, Zhang J, Li F, Wang K, Qin X, et al: HZ08 reverse the
aneuploidy-induced cisplatin-resistance in Gastric cancer by
modulating the p53 pathway. Eur J Pharmacol. 720:84–97. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee JY, Hong M, Kim ST, Park SH, Kang WK,
Kim KM and Lee J: The impact of concomitant genomic alterations on
treatment outcome for trastuzumab therapy in HER2-positive gastric
cancer. Sci Rep. 5:92892015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Won E, Janjigian YJ and Ilson DH: HER2
directed therapy for gastric/esophageal cancers. Curr Treat Options
Oncol. 15:395–404. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dong H, Liu G, Jiang B, Guo J, Tao G, Yiu
W, Zhou J and Li G: Overexpression of the Survivin gene in SGC7901
cell resistance to cisplatin. Oncol Lett. 8:1953–1956.
2014.PubMed/NCBI
|
|
14
|
Sun XP, Dong X, Lin L, Jiang X, Wei Z,
Zhai B, Sun B, Zhang Q, Wang X, Jiang H, et al: Up-regulation of
survivin by AKT and hypoxia-inducible factor 1α contributes to
cisplatin resistance in gastric cancer. FEBS J. 281:115–128. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Spick C, Herrmann K and Czernin J: 18F-FDG
PET/CT and PET/MRI perform equally well in cancer: Evidence from
studies on more than 2,300 patients. J Nucl Med. 57:420–430. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kitasato Y, Yasunaga M, Okuda K, Kinoshita
H, Tanaka H, Okabe Y, Kawahara A, Kage M, Kaida H and Ishibashi M:
Maximum standardized uptake value on
18F-fluoro-2-deoxy-glucose positron emission
tomography/computed tomography and glucose transporter-1 expression
correlates with survival in invasive ductal carcinoma of the
pancreas. Pancreas. 43:1060–1065. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Duan XY, Wang W, Wang JS, Shang J, Gao JG
and Guo YM: Fluorodeoxyglucose positron emission tomography and
chemotherapy-related tumor marker expression in non-small cell lung
cancer. BMC Cancer. 13:5462013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao JG, Hu Y, Liao Q, Niu ZY and Zhao YP:
Prognostic significance of SUVmax and serum carbohydrate antigen
19-9 in pancreatic cancer. World J Gastroenterol. 20:5875–5880.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Caglar M, Yener C and Karabulut E: Value
of CT, FDG PET-CT and serum tumor markers in staging recurrent
colorectal cancer. Int J CARS. 10:993–1002. 2015. View Article : Google Scholar
|
|
20
|
Tomita M, Shimizu T, Ayabe T and Onitsuka
T: Maximum SUV on positron emission tomography and serum CEA level
as prognostic factors after curative resection for non-small cell
lung cancer. Asia Pac J Clin Oncol. 8:244–247. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kuruva M, Mittal BR, Abrar ML, Kashyap R
and Bhattacharya A: Multivariate analysis of various factors
affecting background liver and mediastinal standardized uptake
values. Indian J Nucl Med. 27:20–23. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wahl RL, Jacene H, Kasamon Y and Lodge MA:
From RECIST to PERCIST: Evolving considerations for PET response
criteria in solid tumors. J Nucl Med. 50 Suppl 1:S122–S150. 2009.
View Article : Google Scholar
|
|
23
|
Hwang JP, Lim I, Kong CB, Jeon DG, Byun
BH, Kim BI, Choi CW and Lim SM: Prognostic value of SUVmax measured
by pretreatment fluorine-18 fluorodeoxyglucose positron emission
tomography/computed tomography in patients with Ewing sarcoma. PLoS
One. 11:e01532812016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Remmele W and Stegner HE: Recommendation
for uniform definition of an immunoreactive score (IRS) for
immunohistochemical estrogen receptor detection (ER-ICA) in breast
cancer tissue. Pathologe. 8:138–140. 1987.(In German). PubMed/NCBI
|
|
25
|
Cheng AN, Jiang SS, Fan CC, Lo YK, Kuo CY,
Chen CH, Liu YL, Lee CC, Chen WS, Huang TS, et al: Increased Cdc7
expression is a marker of oral squamous cell carcinoma and
overexpression of Cdc7 contributes to the resistance to
DNA-damaging agents. Cancer Lett. 337:218–225. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wesoła M and Jeleń M: A comparison of IHC
and FISH cytogenetic methods in the evaluation of HER2 status in
breast cancer. Adv Clin Exp Med. 24:899–903. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hofmann M, Stoss O, Shi D, Büttner R, van
de Vijver M, Kim W, Ochiai A, Rüschoff J and Henkel T: Assessment
of a HER2 scoring system for gastric cancer: Results from a
validation study. Histopathology. 52:797–805. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kim JH, Jun KH, Jung H, Park IS and Chin
HM: Prognostic value of preoperative serum levels of five tumor
markers (carcinoembryonic antigen, CA19-9, alpha-fetoprotein,
CA72-4, and CA125) in gastric cancer. Hepatogastroenterology.
61:863–869. 2014.PubMed/NCBI
|
|
29
|
Schmidt-Hansen M, Baldwin DR, Hasler E,
Zamora J, Abraira V and Roqué i Figuls M: PET-CT for assessing
mediastinal lymph node involvement in patients with suspected
resectable non-small cell lung cancer. Cochrane Database Syst Rev.
11:CD0095192014.
|
|
30
|
Coleman RE: Value of FDG-PET scanning in
management of lung cancer. Lancet. 359:1361–1362. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Avril S, Muzic RF Jr, Plecha D, Traughber
BJ, Vinayak S and Avril N: 18 F-FDG PET/CT for monitoring of
treatment response in breast cancer. J Nucl Med. 57(Suppl 1):
S34–S39. 2016. View Article : Google Scholar
|
|
32
|
Kim JW, Oh JS, Roh JL, Kim JS, Choi SH,
Nam SY and Kim SY: Prognostic significance of standardized uptake
value and metabolic tumour volume on 18F-FDG PET/CT in
oropharyngeal squamous cell carcinoma. Eur J Nucl Med Mol Imaging.
42:1353–1361. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Agelaki S, Kalykaki A, Markomanolaki H,
Papadaki MA, Kallergi G, Hatzidaki D, Kalbakis K, Mavroudis D and
Georgoulias V: Efficacy of lapatinib in therapy-resistant
HER2-positive circulating tumor cells in metastatic breast cancer.
PLoS One. 10:e01236832015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cui H, Cheng Y, Piao SZ, Xu YJ, Sun HH,
Cui X, Li XZ, Zhang SN, Piao LZ, Jin YM, et al: Correlation between
HER-2/neu (erbB-2) expression level and therapeutic effect of
combination treatment with HERCEPTIN and chemotherapeutic agents in
gastric cancer cell lines. Cancer Cell Int. 14:102014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Meza-Junco J, Au HJ and Sawyer MB:
Trastuzumab for gastric cancer. Expert Opin Biol Ther. 9:1543–1551.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gong J, Liu T, Fan Q, Bai L, Bi F, Qin S,
Wang J, Xu N, Cheng Y, Bai Y, et al: Optimal regimen of trastuzumab
in combination with oxaliplatin/capecitabine in first-line
treatment of HER2-positive advanced gastric cancer (CGOG1001): A
multicenter, phase II trial. BMC Cancer. 16:682016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kim JY, Lee SH, Kim S, Kang T and Bae YT:
Tumour 18F-FDG uptake on preoperative PET/CT may predict
axillary lymph node metastasis in ER-positive/HER2-negative and
HER2-positive breast cancer subtypes. Eur Radiol. 25:1172–1181.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yoon HJ, Kang KW, Chun IK, Cho N, Im SA,
Jeong S, Lee S, Jung KC, Lee YS, Jeong JM, et al: Correlation of
breast cancer subtypes, based on estrogen receptor, progesterone
receptor, and HER2, with functional imaging parameters from
68Ga-RGD PET/CT and 18F-FDG PET/CT. Eur J
Nucl Med Mol Imaging. 41:1534–1543. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kim CW, Lu JN, Go SI, Jung JH, Yi SM,
Jeong JH, Hah YS, Han MS, Park JW, Lee WS, et al: p53 restoration
can overcome cisplatin resistance through inhibition of Akt as well
as induction of Bax. Int J Oncol. 43:1495–1502. 2013.PubMed/NCBI
|
|
40
|
Koo HR, Park JS, Kang KW, Han W, Park IA
and Moon WK: Correlation between (18)F-FDG uptake on PET/CT and
prognostic factors in triple-negative breast cancer. Eur Radiol.
25:3314–3321. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Altieri DC: Survivin, cancer networks and
pathway-directed drug discovery. Nat Rev Cancer. 8:61–70. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chen X, Duan N, Zhang C and Zhang W:
Survivin and tumorigenesis: Molecular mechanisms and therapeutic
strategies. J Cancer. 7:314–323. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Shen X, Zheng JY, Shi H, Zhang Z and Wang
WZ: Survivin knockdown enhances gastric cancer cell sensitivity to
radiation and chemotherapy in vitro and in nude mice. Am J Med Sci.
344:52–58. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Vallböhmer D, Drebber U, Schneider PM,
Baldus S, Bollschweiler E, Brabender J, Warnecke-Eberz U, Mönig S,
Hölscher AH and Metzger R: Survivin expression in gastric cancer:
Association with histomorphological response to neoadjuvant therapy
and prognosis. J Surg Oncol. 99:409–413. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Malibari N, Hickeson M and Lisbona R:
PET/computed tomography in the diagnosis and staging of gastric
cancers. PET Clin. 10:311–326. 2015. View Article : Google Scholar : PubMed/NCBI
|
